市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Galecto, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.50 |
|
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.69% |
| 机构持股比例 | 13.02% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Jain Global Llc | 31 Dec 2025 | 120,566 |
| Remedium Capital Partners, Llc | 31 Dec 2025 | 120,473 |
| Sigma Planning Corp | 31 Dec 2025 | 14,500 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 46.00 (Leerink Partners, 59.11%) | 购买 |
| 中 | 45.00 (55.66%) | |
| 低 | 40.00 (Guggenheim, 38.36%) | 购买 |
| 平均值 | 43.67 (51.06%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 26.94 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 17 Feb 2026 | 40.00 (38.36%) | 购买 | 29.91 |
| UBS | 17 Feb 2026 | 45.00 (55.66%) | 购买 | 29.91 |
| Leerink Partners | 07 Jan 2026 | 46.00 (59.11%) | 购买 | 21.00 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Jan 2026 | 公告 | Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones |
| 06 Jan 2026 | 公告 | Galecto Announces Key Additions to Leadership Team |
| 16 Dec 2025 | 公告 | Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合